RxDoctor Payments Data

Suhas Bhat, MD

Interventional Cardiology · Ames, IANPI 1952512014

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 96.2% of the total across 29 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 10 manufacturers reported payments, led by Boston Scientific at 49.2% of the total. 2025 is the largest year on record at $165, 2.2 times the $73 reported in 2019. That places this record below the midpoint for interventional cardiology clinicians in IA, where the typical reported total is $3,872.

$457in general payments, 2019–2025

Across 29 payments — averaging $15.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$225
  • Novartis$68
  • Philips North America LLC$31
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$27
  • Boehringer Ingelheim$22
  • Medtronic$21
  • plus $64 from 4 others

What the payments were for

  • Food & beverage$44096%
  • Education$174%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$457 in reported general payments places this provider in the 10th percentile of 64 interventional cardiology providers in Iowa.

See all interventional cardiology providers in Iowa

Medicare billing

Part B allowed, 2024
$413,793
Medicare patients
1,623
Services billed
7,171

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban527$490,753
XareltoRivaroxaban110$124,725
Repatha SureclickEvolocumab54$37,478
BrilintaTicagrelor46$31,460
Metoprolol Succinate733$8,724
Dofetilide27$4,557
Atorvastatin Calcium520$3,675
Dabigatran EtexilateDabigatran Etexilate Mesylate20$3,412
Rosuvastatin Calcium300$3,385
Bumetanide77$3,003
Amiodarone Hcl99$2,887
Amlodipine Besylate504$2,489
Ezetimibe80$2,353
Bisoprolol Fumarate95$2,331
Losartan Potassium292$2,115

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto$16$124,725110 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 10th percentile of 64 interventional cardiology providers in Iowa.

Other interventional cardiology in Ames

See the full list for Iowa

Where these figures come from

Is this you, or does something look wrong? →